Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union
Stopped Significant risks (e.g., infection, endothelial cell loss) and high rate of channel plugging associated with product use.
Conditions
Interventions
- DEVICE: Beacon Aqueous Microshunt
Sponsor
MicroOptx